These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26819216)

  • 21. Strategic R&D transactions in personalized drug development.
    Makino T; Lim Y; Kodama K
    Drug Discov Today; 2018 Jul; 23(7):1334-1339. PubMed ID: 29574213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.
    Choudhury MC; Saberwal G
    Orphanet J Rare Dis; 2019 Nov; 14(1):241. PubMed ID: 31684990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges in orphan drug development and regulatory policy in China.
    Cheng A; Xie Z
    Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs.
    Kesselheim AS; Tan YT; Avorn J
    Health Aff (Millwood); 2015 Feb; 34(2):286-93. PubMed ID: 25646109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm.
    Okuyama R
    Biol Pharm Bull; 2023; 46(5):718-724. PubMed ID: 37121698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An interview with Dr. Edward Abrahams on companion and complementary diagnostics in the era of personalized medicine.
    Abrahams E
    Expert Rev Mol Diagn; 2020 Jun; 20(6):561-563. PubMed ID: 32148107
    [No Abstract]   [Full Text] [Related]  

  • 30. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemical genetics and orphan genetic diseases.
    Lunn MR; Stockwell BR
    Chem Biol; 2005 Oct; 12(10):1063-73. PubMed ID: 16242649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R&D and market size: Who benefits from orphan drug legislation?
    Gamba S; Magazzini L; Pertile P
    J Health Econ; 2021 Dec; 80():102522. PubMed ID: 34530381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

  • 37. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
    Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs.
    Brylinski M; Naderi M; Govindaraj RG; Lemoine J
    J Mol Biol; 2018 Jul; 430(15):2266-2273. PubMed ID: 29237557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-to-Consumer Genetic Testing and Orphan Drug Development.
    Mason M; Levenson J; Quillin J
    Genet Test Mol Biomarkers; 2017 Aug; 21(8):456-463. PubMed ID: 28696792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
    Wood J; Sames L; Moore A; Ekins S
    Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.